TER-1754
Phase 1Small molecule
TER-1754 is one of 20 small molecule programs targeting Hereditary Hemorrhagic Telangiectasia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Hereditary Hemorrhagic Telangiectasia
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Bactroban
PPadagis LLC
Approved
Avastin
BBio-Thera Solutions
Phase 3
Votrient
NovartisPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Nolvadex
AstraZenecaPhase 2
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Sandostatin
Sun PharmaPhase 2
Ofev
Boehringer IngelheimPhase 2
Cyklokapron
AAmring
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TER-1754. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TTerremoto Biosciences Inc.